Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GNG2 | P59768 | 1/20 | 0.37 |
| ▸ | GNB1 | P62873 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL866128 | 0.95 | NPC1 (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL26669751 | 0.89 | NPC1 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10158645 | 0.84 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13092307 | 0.84 | P2RX7 (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11492053 | 0.82 | TAAR1 (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13332559 | 0.80 | HSD17B1 (0.51) | HSD17B1ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL11810833 | 0.80 | MEN1 (0.52) | HSD17B1KMT2ANPSR1MEN1 | |
| Benzylamine SCHEMBL15270988 | 0.79 | LOXL2 (0.48) | NPC1RAB9AALDH1A1KMT2AKDM4E | |
| SCHEMBL10290603 | 0.79 | MAPT (0.48) | NPC1RAB9AHSD17B1ALDH1A1GNG2 | |
| SCHEMBL6193935 | 0.79 | NPC1 (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023077678-A1 | SMALL MOLECULE COMPOUND TARGETING SRSF6 PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2023-05-11 | — | — | WO | claimed |
| CN-115677577-A | Small molecular compound targeting SRSF6 protein, and preparation method and application thereof | 中国药科大学 | 2023-02-03 | — | — | CN | claimed |
| CN-115677577-B | Small molecule compound of targeted SRSF6 protein and preparation method and application thereof | 中国药科大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023077678-A1 | SMALL MOLECULE COMPOUND TARGETING SRSF6 PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2023-05-11 | — | — | WO | disclosed |
| CN-110713991-B | Application of carbonyl reductase and mutant thereof in synthesis of indacaterol drug intermediate | 中国科学院天津工业生物技术研究所 | 2022-01-25 | — | — | CN | disclosed |
| EP-3848354-A1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2021-07-14 | — | — | EP | disclosed |
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | CRYSTAL PHARMA S.A.U. (ES) | 2018-08-07 | — | — | US | disclosed |
| CN-107868045-A | A kind of preparation method of QAB-149 intermediate | 四川海思科制药有限公司 | 2018-04-03 | — | — | CN | disclosed |
| EP-2897937-B1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | CRYSTAL PHARMA SAU (ES) | 2017-12-06 | — | — | EP | disclosed |
| US-20170015628-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CRYSTAL PHARMA S.A.U. (ES) | 2017-01-19 | — | — | US | disclosed |
| EP-1341542-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002045703-A2 | MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENTOF AIRWAY DISEASES | NOVARTIS AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040765-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | SQLE, HSD11B1, CYP51A1 | GRIN2D 4392/4885GRIN3B 3158/4885GRIN1 4569/4885 |
| US-20170015628-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SQLE, HSD11B1, CYP51A1 | GRIN2D 4392/4885GRIN3B 3158/4885GRIN1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.